These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Salivary duct carcinoma responding to trastuzumab-based therapy: case report and review of the literature.
    Author: Krishnamurthy J, Krishnamurty DM, Baker JJ, Zhen W, Lydiatt D, Ganti AK.
    Journal: Head Neck; 2013 Dec; 35(12):E372-5. PubMed ID: 23765450.
    Abstract:
    BACKGROUND: Salivary duct carcinoma (SDC) is a rare malignancy with a poor prognosis. Human epidermal growth factor receptor-2 (Her-2/neu) is overexpressed in SDC and, hence, HER-2/neu targeted therapy could be an option. METHODS: A 72-year-old man presented with parotid swelling and cervical lymphadenopathy. He underwent a parotidectomy, modified radical neck dissection, and postoperative chemoradiation with cisplatin. A year later, he developed metastatic disease in the contralateral neck that was treated surgically with right axillary lymphadenopathy. He received radiation to both sites, concurrent with carboplatin. Two years later, he underwent resection of a lung metastasis. He then had progression in the axillary and mediastinal lymph nodes and received 5 cycles of docetaxel and trastuzumab followed by maintenance trastuzumab. RESULTS: The patient had a partial response and restaging studies 9 months after therapy discontinuation did not show progression. CONCLUSION: Trastuzumab-based therapy is a potential therapeutic option for patients with SDC.
    [Abstract] [Full Text] [Related] [New Search]